IBL-202

N/A

Report date: 2022/11/11 15:28:03
NME

Base Information

Drug NameIBL-202
Drug Alias NameIBL-202
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProto-oncogene serine/threonine-protein kinase Pim-1 inhibitorsPI3-kinase class I inhibitors
TargetsProto-oncogene serine/threonine-protein kinase Pim-1PI3-kinase class I
Therapy Area/IndicationsLeukemia, Lymphocytic, Chronic, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIreland
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesInflection Biosciences LtdAUM Biosciences Pte Ltd
China Registration ClassN/A

Develop Information

Active CompaniesInflection Biosciences Ltd
Inactive CompaniesN/A
Active IndicationsLeukemia, Lymphocytic, Chronic, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A